Analyst Research

Report Title Price
Thomson Reuters Stock Report - OCLARO, INCORPORATION (OCLR-O)
Provider: Thomson Reuters Stock Report
$25.00
Buy
OCLARO INC (OCLR) 12-months forecast
Provider: Pechala's Reports
$15.00
Buy
Oclaro Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
$20.00
Buy
OCLARO INC (OCLR) Zacks Company Snapshot
Provider: Zacks Investment Research Inc.
$12.00
Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Oclaro Inc Issues Q2 2013 Guidance In Line With Analysts' Estimates


Monday, 5 Nov 2012 04:05pm EST 

Oclaro Inc announced that for second quarter 2013, revenues in the range of $145-$162 million, adjusted EBITDA in the range of negative $20-negative $9million. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $158 million and EBITDA of $(11) million for second quarter of 2013. 

Latest Developments for Oclaro Inc

Latest Key Developments in Medical

Company Quote

Oclaro Inc
(OCLR.OQ)
1.09
-0.01 -0.91%
4:00pm EDT